Following The Publication Trail of Two RSV Drugs
In a publication from 2007, investigators from Arrow Pharmaceuticals told us that A-60444 (later renamed to RSV-604) was already in Phase 2. Since then, it has been very quiet about this compound. Some have suggested that Novartis has stopped development [1], an impression supported by the fact that the drug is Continue reading Following The Publication Trail of Two RSV Drugs